IS2049B - Notkun amína til að framleiða lyf til að koma í veg fyrir fjölgun æxlisfrumna - Google Patents

Notkun amína til að framleiða lyf til að koma í veg fyrir fjölgun æxlisfrumna

Info

Publication number
IS2049B
IS2049B IS4946A IS4946A IS2049B IS 2049 B IS2049 B IS 2049B IS 4946 A IS4946 A IS 4946A IS 4946 A IS4946 A IS 4946A IS 2049 B IS2049 B IS 2049B
Authority
IS
Iceland
Prior art keywords
amines
cell proliferation
tumor cell
prevent tumor
produce drugs
Prior art date
Application number
IS4946A
Other languages
English (en)
Other versions
IS4946A (is
Inventor
Breliere Jean-Claude
Ferrara Pascual
Lebouteiller Christine
Paul Raymond
Rosenfeld Jorge
Van Broeck Didier
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of IS4946A publication Critical patent/IS4946A/is
Publication of IS2049B publication Critical patent/IS2049B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IS4946A 1996-07-29 1999-01-19 Notkun amína til að framleiða lyf til að koma í veg fyrir fjölgun æxlisfrumna IS2049B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609531A FR2751645B1 (fr) 1996-07-29 1996-07-29 Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
PCT/FR1997/001409 WO1998004251A1 (fr) 1996-07-29 1997-07-28 Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales

Publications (2)

Publication Number Publication Date
IS4946A IS4946A (is) 1999-01-19
IS2049B true IS2049B (is) 2005-09-15

Family

ID=9494593

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4946A IS2049B (is) 1996-07-29 1999-01-19 Notkun amína til að framleiða lyf til að koma í veg fyrir fjölgun æxlisfrumna

Country Status (31)

Country Link
US (1) US6235791B1 (is)
EP (1) EP0917464B1 (is)
JP (1) JP3538431B2 (is)
KR (1) KR100315559B1 (is)
CN (1) CN1154483C (is)
AR (1) AR008090A1 (is)
AT (1) ATE266392T1 (is)
AU (1) AU735948B2 (is)
BR (1) BR9711606A (is)
CA (1) CA2261827C (is)
CZ (1) CZ294266B6 (is)
DE (1) DE69729099T2 (is)
DK (1) DK0917464T3 (is)
EE (1) EE03851B1 (is)
ES (1) ES2221061T3 (is)
FR (1) FR2751645B1 (is)
HU (1) HU224346B1 (is)
ID (1) ID17707A (is)
IL (1) IL127922A (is)
IS (1) IS2049B (is)
MY (1) MY120426A (is)
NO (1) NO322897B1 (is)
NZ (1) NZ333957A (is)
PT (1) PT917464E (is)
RU (1) RU2176502C2 (is)
SI (1) SI0917464T1 (is)
SK (1) SK285344B6 (is)
TR (1) TR199900161T2 (is)
UA (1) UA61080C2 (is)
WO (1) WO1998004251A1 (is)
ZA (1) ZA976697B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2143403B1 (es) * 1998-03-13 2001-01-01 Consejo Superior Investigacion Derivados de ciclopropenilaminas como agentes anticancerosos.
GB9814036D0 (en) 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
FR2794742B1 (fr) 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2795724B1 (fr) * 1999-07-02 2002-12-13 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
ATE327673T1 (de) * 2001-08-23 2006-06-15 Bayer Cropscience Sa Substituierte propargylamine
FR2887454B1 (fr) * 2005-06-28 2009-06-05 Sanofi Aventis Sa Combinaisons antitumorales contenant des derives du taxane et des sigma ligands
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
EP2126574B1 (en) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
AU2013299330B2 (en) * 2012-08-01 2018-01-25 Merck Sharp & Dohme Llc Alpha7 nicotinic acetylcholine receptor modulators and uses thereof-i
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
MX2018011453A (es) 2016-03-22 2019-01-10 Merck Sharp & Dohme Moduladores alostericos de receptores de acetilcolina nicotinicos.
JP2023541960A (ja) 2020-09-17 2023-10-04 メレティオス セラピューティクス ウイルス感染を治療するための化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674832A (en) 1968-08-22 1972-07-04 Schering Corp Cyclopropane carboxylic acid derivatives
FR2132547A1 (en) 1971-04-08 1972-11-24 Clin Byla Ets Substd phenyl alkyl or alkenyl amides - useful as analgesics and antiinflammatories
GB1475314A (en) * 1973-11-02 1977-06-01 Cm Ind Phenyl-propylamine derivatives
US4104383A (en) 1973-11-02 1978-08-01 C M Industries Derivatives of phenylpropenylamine
IT1113391B (it) 1979-05-09 1986-01-20 Maggioni Farma Derivati fenilcicloesanici ad attivita' antidepressiva
US4537902A (en) * 1979-06-11 1985-08-27 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
FR2641276B1 (fr) 1988-12-30 1991-07-12 Sanofi Sa Derives du benzene, leur preparation et les compositions pharmaceutiques en contenant
JP2814694B2 (ja) 1989-07-21 1998-10-27 セイコーエプソン株式会社 識別コード読み書き構造及びその装置及びその方法
FR2663328B1 (fr) * 1990-06-14 1994-08-05 Sanofi Sa Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2694287B1 (fr) * 1992-07-31 1994-09-16 Jouveinal Inst Rech Nouvelles cycloalkylalkylamines ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique.
US5849760A (en) * 1993-12-09 1998-12-15 Institut De Recherche Jouveinal 2-(arylalkenyl)azacycloalkane derivatives as ligands for sigma receptors
FR2724656B1 (fr) * 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2725445B1 (fr) * 1994-10-10 1996-10-31 Adir Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5919934A (en) * 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy

Also Published As

Publication number Publication date
AR008090A1 (es) 1999-12-09
FR2751645B1 (fr) 1998-12-24
HUP9902806A3 (en) 2000-12-28
US6235791B1 (en) 2001-05-22
UA61080C2 (uk) 2003-11-17
RU2176502C2 (ru) 2001-12-10
CZ294266B6 (cs) 2004-11-10
IL127922A (en) 2003-11-23
EE9900029A (et) 1999-08-16
NO322897B1 (no) 2006-12-07
EP0917464A1 (fr) 1999-05-26
ID17707A (id) 1998-01-22
JP3538431B2 (ja) 2004-06-14
BR9711606A (pt) 1999-08-24
PT917464E (pt) 2004-08-31
FR2751645A1 (fr) 1998-01-30
ZA976697B (en) 1998-02-10
IS4946A (is) 1999-01-19
HU224346B1 (hu) 2005-08-29
IL127922A0 (en) 1999-11-30
AU3855197A (en) 1998-02-20
SI0917464T1 (en) 2004-12-31
DE69729099D1 (de) 2004-06-17
CZ24299A3 (cs) 1999-05-12
WO1998004251A1 (fr) 1998-02-05
ATE266392T1 (de) 2004-05-15
AU735948B2 (en) 2001-07-19
TR199900161T2 (xx) 1999-04-21
CN1154483C (zh) 2004-06-23
MY120426A (en) 2005-10-31
SK285344B6 (sk) 2006-11-03
EE03851B1 (et) 2002-10-15
EP0917464B1 (fr) 2004-05-12
CN1226825A (zh) 1999-08-25
HU9902806A (en) 2000-04-28
SK7999A3 (en) 2000-01-18
CA2261827C (fr) 2004-10-26
CA2261827A1 (fr) 1998-02-05
DE69729099T2 (de) 2005-05-12
NO990401L (no) 1999-03-25
ES2221061T3 (es) 2004-12-16
KR100315559B1 (ko) 2001-12-12
DK0917464T3 (da) 2004-08-16
NO990401D0 (no) 1999-01-28
NZ333957A (en) 2000-09-29
KR20000029629A (ko) 2000-05-25
JP2000500782A (ja) 2000-01-25

Similar Documents

Publication Publication Date Title
IS2049B (is) Notkun amína til að framleiða lyf til að koma í veg fyrir fjölgun æxlisfrumna
IS5656A (is) Innlimun virkra efna í burðarmatrixur
ID17128A (id) Granulat untuk pembuatan komposisi-komposisi cepat mengurai dan cepat larut yang mengandung jumlah obat yang tinggi
IS6083A (is) Notkun á CYP2D6 lötum í samsetningarmeðferðum
DE69728057D1 (de) Iontophoretische auslösbare lieferungsvorrichtung zur verminderung von elektrischen empfindungen
ATE220545T1 (de) Fentanyl enthaltendes transdermal-pflaster
IS4731A (is) Kínólín og kínazólín efnasambönd nytsamleg í meðferð
DE69735643D1 (de) IL12 zur Gentherapie der Tumoren
DE19882627T1 (de) Stimulation linsenförmiger Erdgasformationen
IS5097A (is) Fenófíbrat lyfjasamsetning með háa lífeðlisfræðilega upptöku og aðferð til framleiðslu hennar
DK147486A (da) Fremgangsmaade og system til delmaaling af energiforbrug
BR9706129A (pt) 3-Hidroxiprina-2-Carboxamidoésteres preparação deles e uso dos mesmos como substâncias farmacêuticas
IS4365A (is) Lyfjablöndur og lyf til að hindra og meðhöndla starfstruflun í innanþekju (endothelial dysfunctions)
BR9711296A (pt) Composto processo terap-utico para inibir o crescimento de c-lulas de c ncer e composi-Æo farmac-utica
IS5496A (is) Notkun útskiptra amínómetýl krómanefna til að koma í veg fyrir taugahrörnun og til að hvetja endurmyndun tauga
DK568287D0 (da) Relativt lavmolekylaere peptider og deres anvendelse som renininhibitorer
DE59500266D1 (de) Transdermales therapeutisches System zur Applikation von Naloxon
DK1009750T3 (da) Nye (alfa-aminophosphino)peptid derivater, fremgangsmåde til deres fremstilling og deres terapeutiske anvendelse
IS5349A (is) Blöndur, samstæður og aðferðir til að hindra sjúkdóma í heilaæðum og taugum og vöðva-höfuðverki
KR950703064A (ko) 세포증식의 저해물질, 그의 제조방법 및 이용방법
IT8967664A0 (it) Supporto asismico ad alta stabilita
DE69809945D1 (de) Verwendung von ergosterol und von verwandten verbindungen zur förderung der proliferation von hautzellen
DK241490A (da) Peptid-inhibitorer af hiv-inducerede cellefusioner og syncytiedannelse
ID27014A (id) Metode yang lebih baik untuk pembuatan turunan-turunan norbenzomorfana yang bermanfaat secara farmasi
DE69703832D1 (de) Verwendiung eines amins zur verbesserung von paraformaldehyd